Literature DB >> 8492318

Relationship of c-myc amplification to progression of breast cancer from in situ to invasive tumor and lymph node metastasis.

P H Watson1, J R Safneck, K Le, D Dubik, R P Shiu.   

Abstract

BACKGROUND: Amplification of the c-myc gene (also known as MYC) occurs in up to 20%-30% of breast cancers and has been associated with poor prognosis.
PURPOSE: The purpose of this study was to define the relationship between c-myc amplification and breast cancer progression in order to better understand the biological significance of c-myc amplification.
METHODS: We identified invasive tumors with grossly detectable c-myc amplification by using Southern blot analysis to examine frozen tissue from 135 breast carcinomas and polymerase chain reaction (PCR) analysis to examine archival paraffin-embedded tissue from an additional 19 invasive tumors. These 19 tumors were selected on the basis of histologically identifiable in situ and invasive components within the primary tumor and associated lymph node metastases. Amplification of c-myc in these areas was then assessed by quantitative PCR assay.
RESULTS: We detected gross c-myc amplification in 10 of the tumors examined--eight of the 135 frozen tissue specimens and two of the 19 archival specimens. We selected five of these 10 invasive tumors for further regional analysis. In all four cases where an in situ component was present, amplification of c-myc was present in both the in situ and the invasive components. However, c-myc amplification was present in the corresponding nodal metastases in only two of the four cases where this could be examined.
CONCLUSION: These results suggest that c-myc amplification can occur at an early stage in tumor progression and that amplification does not always persist in the nodal metastasis.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8492318     DOI: 10.1093/jnci/85.11.902

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  13 in total

1.  B lymphocyte-specific c-Myc expression stimulates early and functional expansion of the vasculature and lymphatics during lymphomagenesis.

Authors:  Alanna Ruddell; Pau Mezquita; Kimberly A Brandvold; Andrew Farr; Brian M Iritani
Journal:  Am J Pathol       Date:  2003-12       Impact factor: 4.307

2.  Genetic changes in intraductal breast cancer detected by comparative genomic hybridization.

Authors:  T Kuukasjärvi; M Tanner; S Pennanen; R Karhu; O P Kallioniemi; J Isola
Journal:  Am J Pathol       Date:  1997-04       Impact factor: 4.307

3.  Consistent MYC and FLT4 gene amplification in radiation-induced angiosarcoma but not in other radiation-associated atypical vascular lesions.

Authors:  Tianhua Guo; Lei Zhang; Ning-En Chang; Samuel Singer; Robert G Maki; Cristina R Antonescu
Journal:  Genes Chromosomes Cancer       Date:  2011-01       Impact factor: 5.006

Review 4.  Next-generation sequencing: a powerful tool for the discovery of molecular markers in breast ductal carcinoma in situ.

Authors:  Hitchintan Kaur; Shihong Mao; Seema Shah; David H Gorski; Stephen A Krawetz; Bonnie F Sloane; Raymond R Mattingly
Journal:  Expert Rev Mol Diagn       Date:  2013-03       Impact factor: 5.225

Review 5.  Immunohistochemical studies of early breast cancer evolution.

Authors:  D C Allred; P O'Connell; S A Fuqua; C K Osborne
Journal:  Breast Cancer Res Treat       Date:  1994       Impact factor: 4.872

6.  Combined analysis of copy number alterations by single-nucleotide polymorphism array and MYC status in non-metastatic breast cancer patients: comparison according to the circulating tumor cell status.

Authors:  R Nadal; M Salido; L Nonell; M Rodríguez-Rivera; E Puigdecanet; J L Garcia-Puche; M Macià; J M Corominas; M J Serrano; J A Lorente; F Solé
Journal:  Tumour Biol       Date:  2014-10-07

7.  Classical gene amplifications in human breast cancer are not associated with distant solid metastases.

Authors:  K Driouch; M H Champème; M Beuzelin; I Bièche; R Lidereau
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

Review 8.  Myc and the Replicative CMG Helicase: The Creation and Destruction of Cancer: Myc Over-Activation of CMG Helicases Drives Tumorigenesis and Creates a Vulnerability in CMGs for Therapeutic Intervention.

Authors:  Damon R Reed; Mark G Alexandrow
Journal:  Bioessays       Date:  2020-02-20       Impact factor: 4.345

9.  Reversal by RARα agonist Am580 of c-Myc-induced imbalance in RARα/RARγ expression during MMTV-Myc tumorigenesis.

Authors:  Almudena Bosch; Silvina P Bertran; Yongke Lu; Avalon Garcia; Alexis M Jones; Marcia I Dawson; Eduardo F Farias
Journal:  Breast Cancer Res       Date:  2012-08-24       Impact factor: 6.466

10.  Moderate amplifications of the c-myc gene correlate with molecular and clinicopathological parameters in colorectal cancer.

Authors:  L Masramon; R Arribas; S Tórtola; M Perucho; M A Peinado
Journal:  Br J Cancer       Date:  1998-06       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.